Skip to main content

Advertisement

SpringerLink
Log in

Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Autoimmune hepatitis has a variable occurrence, clinical phenotype, and outcome, and the factors contributing to this variability are uncertain. The goals of this review are to examine the global disparities in the occurrence and outcome of autoimmune hepatitis, suggest bases for these disparities, and encourage investigations that extend beyond single-center experiences. Disparities in the incidence and prevalence of autoimmune hepatitis in different age groups, genders, ethnicities, and geographical regions suggest that factors other than genetic predisposition are involved. Age- and gender-related antigen exposures from the external (infections, toxins, and medications) and internal (intestinal microbiome) environment may affect the incidence of the disease, and the timeliness and nature of treatment may influence its prevalence. The increasing incidence of autoimmune hepatitis in Spain, Denmark, and the Netherlands suggests that a new etiological trigger has been introduced or that the susceptible population has changed. Variations in mortality between Western and Asian-Pacific countries may result from differences in disease detection or management, and variations in gender predilection, peak age of onset, frequency of concurrent immune diseases, and serological profile may reflect gender-biased and age-related antigen exposures and genetic predispositions. Global collaborations, population-based epidemiological studies that identify case clustering, and controlled interview-based surveys are mechanisms by which to understand these disparities and improve management. In conclusion, autoimmune hepatitis has a rising incidence in some countries and variable occurrence, phenotype, and outcome between countries and subgroups within countries. These disparities suggest that unrecognized population-based environmental, infectious, or socioeconomic factors are affecting its character.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bearn AG, Kunkel HG, Slater RJ. The problem of chronic liver disease in young women. Am J Med. 1956;21:3–15.

    Article  CAS  PubMed  Google Scholar 

  2. Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet. 1956;271:1323–1326.

    CAS  PubMed  Google Scholar 

  3. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;1:65–69.

    Article  CAS  PubMed  Google Scholar 

  4. Mackay IR, Wood IJ. The course and treatment of lupoid hepatitis. Gastroenterology. 1963;45:4–13.

    CAS  PubMed  Google Scholar 

  5. Waldenstrom J. Leber, Blutproteine und Nahrungseiweiss. Dtsch Gesellsch Verdau Stoffwechselkr. 1950;15:113–121.

    Google Scholar 

  6. Bongiovanni AM, Eisenmenger WJ. Adrenal cortical metabolism in chronic liver disease. J Clin Endocrinol Metab. 1951;11:152–172.

    Article  CAS  PubMed  Google Scholar 

  7. Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol. 1966;1:237–262.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Page AR, Condie RM, Good RA. Suppression of plasma cell hepatitis with 6-mercaptopurine. Am J Med. 1964;36:200–213.

    Article  CAS  PubMed  Google Scholar 

  9. Kerr JF, Cooksley WG, Searle J, et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet. 1979;2:827–828.

    Article  CAS  PubMed  Google Scholar 

  10. Willocx RG, Isselbacher KJ. Chronic liver disease in young people. Clinical features and course in thirty-three patients. Am J Med. 1961;30:185–195.

    Article  CAS  PubMed  Google Scholar 

  11. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051–2057.

    Article  CAS  PubMed  Google Scholar 

  12. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008;48:140–147.

    Article  CAS  PubMed  Google Scholar 

  13. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25:541–547.

    Article  CAS  PubMed  Google Scholar 

  14. Schramm C, Kanzler S, zum Buschenfelde KH, et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96:1587–1591.

    Article  CAS  PubMed  Google Scholar 

  15. Granito A, Muratori L, Pappas G, et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther. 2005;21:1273–1277.

    Article  CAS  PubMed  Google Scholar 

  16. Verslype C, George C, Buchel E, et al. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther. 2005;21:695–699.

    Article  CAS  PubMed  Google Scholar 

  17. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575–583.

    Article  PubMed  Google Scholar 

  18. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–538.

    Article  PubMed  Google Scholar 

  19. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25:219–239.

    Article  CAS  PubMed  Google Scholar 

  20. Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol. 2013;7:365–385.

    Article  CAS  PubMed  Google Scholar 

  21. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631.

    Article  PubMed  Google Scholar 

  22. Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci. 2013;58:897–914.

    Article  CAS  PubMed  Google Scholar 

  23. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35:75–81.

    Article  PubMed  Google Scholar 

  24. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.

    Article  PubMed  Google Scholar 

  25. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755–1761.

    Article  CAS  PubMed  Google Scholar 

  26. Heringlake S, Schutte A, Flemming P, et al. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417–423.

    Article  CAS  PubMed  Google Scholar 

  27. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421–3438.

    Article  PubMed  Google Scholar 

  28. Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292–294.

    Article  CAS  PubMed  Google Scholar 

  29. Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA. 1992;89:9739–9743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18:1–9.

    Article  CAS  PubMed  Google Scholar 

  31. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–2161.

    Article  CAS  PubMed  Google Scholar 

  33. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85–92.

    Article  CAS  PubMed  Google Scholar 

  34. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int. 2013;33:190–196.

    Article  CAS  PubMed  Google Scholar 

  35. Kirstein MM, Metzler F, Geiger E, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology. 2015;62:1524–1535.

    Article  CAS  PubMed  Google Scholar 

  36. Zachou K, Gampeta S, Gatselis NK, et al. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int. 2015;35:660–672.

    Article  CAS  PubMed  Google Scholar 

  37. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892–898.

    Article  CAS  PubMed  Google Scholar 

  38. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004;37:195–201.

    Article  CAS  PubMed  Google Scholar 

  39. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–1339.

    Article  CAS  PubMed  Google Scholar 

  40. Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545–554.

    Article  CAS  PubMed  Google Scholar 

  41. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.

    Article  CAS  PubMed  Google Scholar 

  42. Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci. 2012;57:610–624.

    Article  CAS  PubMed  Google Scholar 

  43. Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326–343.

    CAS  PubMed  Google Scholar 

  44. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668.

    Article  CAS  PubMed  Google Scholar 

  45. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270.

    Article  PubMed  Google Scholar 

  46. Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res. 2007;37:801–805.

    Article  CAS  PubMed  Google Scholar 

  47. Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver. 1984;4:105–116.

    Article  CAS  PubMed  Google Scholar 

  49. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659–665.

    Article  CAS  PubMed  Google Scholar 

  50. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004;24:322–329.

    Article  PubMed  Google Scholar 

  51. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis. 2002;6:605–621.

    Article  PubMed  Google Scholar 

  52. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.

    Article  CAS  PubMed  Google Scholar 

  53. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.

    Article  PubMed  Google Scholar 

  54. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  CAS  PubMed  Google Scholar 

  55. Primo J, Maroto N, Martinez M, et al. Incidence of adult form of autoimmune hepatitis in Valencia (Spain). Acta Gastroenterol Belg. 2009;72:402–406.

    CAS  PubMed  Google Scholar 

  56. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49:1245–1254.

    Article  PubMed  CAS  Google Scholar 

  57. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612–617.

    Article  PubMed  Google Scholar 

  58. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.

    Article  CAS  PubMed  Google Scholar 

  59. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242.

    Article  PubMed  Google Scholar 

  60. Bjornsson ES, Ekbom A. Scandinavian epidemiological research in gastroenterology and hepatology. Scand J Gastroenterol. 2015;50:636–648.

    PubMed  Google Scholar 

  61. Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis. 1997;17:13–22.

    Article  CAS  PubMed  Google Scholar 

  62. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188.

    Article  PubMed  Google Scholar 

  63. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145:375e372–382e372.

    Article  Google Scholar 

  64. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002;6:635–647.

    Article  PubMed  Google Scholar 

  65. Primo J, Merino C, Fernandez J, et al. Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain). Gastroenterol Hepatol. 2004;27:239–243.

    Article  CAS  PubMed  Google Scholar 

  66. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232–1240.

    Article  PubMed  Google Scholar 

  67. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010;25:1681–1686.

    Article  PubMed  Google Scholar 

  68. Haider AS, Kaye G, Thomson A. Autoimmune hepatitis in a demographically isolated area of Australia. Intern Med J. 2010;40:281–285.

    Article  CAS  PubMed  Google Scholar 

  69. Delgado JS, Vodonos A, Malnick S, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis. 2013;14:611–618.

    CAS  PubMed  Google Scholar 

  70. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–2407.

    Article  PubMed  Google Scholar 

  71. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.

    Article  CAS  PubMed  Google Scholar 

  72. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–1202.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Zein CO, Beatty K, Post AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology. 2006;44:1564–1571.

    Article  CAS  PubMed  Google Scholar 

  74. Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162–169.

    Article  PubMed  Google Scholar 

  75. Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology. 2006;43:525–531.

    Article  PubMed  Google Scholar 

  76. Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers. 2010;29:337–344.

    Article  PubMed  Google Scholar 

  77. Burroughs AK, Rosenstein IJ, Epstein O, et al. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25:133–137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470–475.

    Article  PubMed  Google Scholar 

  79. Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol. 2016;22:9257–9278.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Jimenez-Rivera C, Ling SC, Ahmed N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics. 2015;136:e1237–e1248.

    Article  PubMed  Google Scholar 

  81. Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–1400.

    Article  PubMed  Google Scholar 

  82. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146–150.

    Article  CAS  PubMed  Google Scholar 

  83. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374–1380.

    Article  CAS  PubMed  Google Scholar 

  84. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302–308.

    Article  PubMed  Google Scholar 

  85. Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001;62:165–169.

    Article  CAS  PubMed  Google Scholar 

  86. Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512–1517.

    Article  CAS  PubMed  Google Scholar 

  87. Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci. 2015;60:2881–2900.

    Article  CAS  PubMed  Google Scholar 

  88. Danielsson Borssen A, Marschall HU, Bergquist A, et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand J Gastroenterol. 2017;52:1022–1028.

    PubMed  Google Scholar 

  89. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–1260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Clark A, Mach N. Role of vitamin D in the hygiene hypothesis: the interplay between vitamin D, vitamin D receptors, gut microbiota, and immune response. Front Immunol. 2016;7:627.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Schramm C, Lohse AW. Autoimmune hepatitis on the rise. J Hepatol. 2014;60:478–479.

    Article  PubMed  Google Scholar 

  92. Weiss ST, Litonjua AA. Vitamin D, the gut microbiome, and the hygiene hypothesis. How does asthma begin? Am J Respir Crit Care Med. 2015;191:492–493.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014;59:3035–3042.

    Article  CAS  PubMed  Google Scholar 

  94. Beyazit Y, Kocak E, Tanoglu A, Kekilli M. Oxidative stress might play a role in low serum vitamin D associated liver fibrosis among patients with autoimmune hepatitis. Dig Dis Sci. 2015;60:1106–1108.

    Article  PubMed  Google Scholar 

  95. Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8:5153–5160.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Chung HV, Riley M, Ho JK, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia’s First Nations community. Can J Gastroenterol. 2007;21:565–568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001;16:1384–1389.

    Article  CAS  PubMed  Google Scholar 

  98. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.

    Article  PubMed  Google Scholar 

  99. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058–1066.

    Article  PubMed  Google Scholar 

  100. Mathur AK, Osborne NH, Lynch RJ, et al. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145:1158–1163.

    Article  PubMed  Google Scholar 

  101. Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev. 2012;11:A386–A392.

    Article  PubMed  Google Scholar 

  102. Miller GE, Engen PA, Gillevet PM, et al. Lower neighborhood socioeconomic status associated with reduced diversity of the colonic microbiota in healthy adults. PLoS ONE. 2016;11:e0148952.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Radhakrishnan KR, Alkhouri N, Worley S, et al. Autoimmune hepatitis in children—impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010;42:724–728.

    Article  PubMed  Google Scholar 

  104. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149–2155.

    Article  CAS  PubMed  Google Scholar 

  105. Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18:342–352.

    Article  CAS  PubMed  Google Scholar 

  106. D’Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int. 2005;25:325–330.

    Article  PubMed  Google Scholar 

  107. Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999;283:1277–1278.

    Article  CAS  PubMed  Google Scholar 

  108. Young NA, Wu LC, Burd CJ, et al. Estrogen modulation of endosome-associated toll-like receptor 8: an IFNalpha-independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol. 2014;151:66–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Tanaka A, Lindor K, Ansari A, Gershwin ME. Fetal microchimerisms in the mother: immunologic implications. Liver Transpl. 2000;6:138–143.

    Article  CAS  PubMed  Google Scholar 

  110. Lambert NC, Evans PC, Hashizumi TL, et al. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol. 2000;164:5545–5548.

    Article  CAS  PubMed  Google Scholar 

  111. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet. 2004;363:533–535.

    Article  PubMed  Google Scholar 

  112. Miozzo M, Selmi C, Gentilin B, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46:456–462.

    Article  CAS  PubMed  Google Scholar 

  113. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400–404.

    Article  CAS  PubMed  Google Scholar 

  114. Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev. 2010;9:494–498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Mitchell MM, Lleo A, Zammataro L, et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics. 2011;6:95–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Yurkovetskiy L, Burrows M, Khan AA, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39:400–412.

    Article  CAS  PubMed  Google Scholar 

  117. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084–1088.

    Article  CAS  PubMed  Google Scholar 

  118. Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes. 2014;5:485–493.

    Article  PubMed  Google Scholar 

  119. Gomez A, Luckey D, Taneja V. The gut microbiome in autoimmunity: sex matters. Clin Immunol. 2015;159:154–162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr. 2014;111:387–402.

    Article  CAS  PubMed  Google Scholar 

  122. Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology. 2005;115:153–162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Van Praet JT, Donovan E, Vanassche I, et al. Commensal microbiota influence systemic autoimmune responses. EMBO J. 2015;34:466–474.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol. 2011;19:427–434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Paronen J, Klemetti P, Kantele JM, et al. Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes. 1997;46:583–588.

    Article  CAS  PubMed  Google Scholar 

  127. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422–433.

    Article  CAS  PubMed  Google Scholar 

  128. Sorini C, Falcone M. Shaping the (auto)immune response in the gut: the role of intestinal immune regulation in the prevention of type 1 diabetes. Am J Clin Exp Immunol. 2013;2:156–171.

    PubMed  PubMed Central  Google Scholar 

  129. Yuksel M, Wang Y, Tai N, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015;62:1536–1550.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut. 1998;42:599–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. McFarlane IG. Autoimmune hepatitis: clinical manifestations and diagnostic criteria. Can J Gastroenterol. 2001;15:107–113.

    Article  CAS  PubMed  Google Scholar 

  132. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701–706.

    Article  CAS  PubMed  Google Scholar 

  133. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028–2035.

    Article  CAS  PubMed  Google Scholar 

  134. van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16:247–252.

    Article  PubMed  CAS  Google Scholar 

  135. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502–1507.

    Article  CAS  PubMed  Google Scholar 

  136. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis. 2002;6:707–725.

    Article  PubMed  Google Scholar 

  137. Bittencourt PL, Farias AQ, Porta G, et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol. 2008;42:300–305.

    PubMed  Google Scholar 

  138. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989–2993.

    Article  CAS  PubMed  Google Scholar 

  139. De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290–296.

    Article  PubMed  Google Scholar 

  140. Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71–96.

    CAS  PubMed  Google Scholar 

  141. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24–26.

    Article  CAS  PubMed  Google Scholar 

  142. Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol. 1992;90:351–354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Mariat D, Firmesse O, Levenez F, et al. The firmicutes/bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 2011;108:4586–4591.

    Article  CAS  PubMed  Google Scholar 

  145. Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE. 2011;6:e23035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.

    Article  CAS  PubMed  Google Scholar 

  147. Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33–48.

    Article  CAS  PubMed  Google Scholar 

  148. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206–1211.

    CAS  PubMed  Google Scholar 

  149. Parveen S, Morshed SA, Arima K, et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci. 1998;43:1322–1331.

    Article  CAS  PubMed  Google Scholar 

  150. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370–1378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Ma Y, Thomas MG, Okamoto M, et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol. 2002;169:277–285.

    Article  CAS  PubMed  Google Scholar 

  152. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290–1295.

    Article  CAS  PubMed  Google Scholar 

  153. Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364–374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–1515.

    Article  CAS  PubMed  Google Scholar 

  155. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59–65.

    Article  CAS  PubMed  Google Scholar 

  156. Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int. 2009;29:857–864.

    Article  CAS  PubMed  Google Scholar 

  157. Ferucci ED, Choromanski TL, Hurlburt KJ, et al. Autoimmune hepatitis in the Alaska Native population: autoantibody profile and HLA associations. Liver Int. 2014;34:1241–1249.

    Article  CAS  PubMed  Google Scholar 

  158. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567–572.

    Article  CAS  PubMed  Google Scholar 

  159. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995;108:1159–1166.

    Article  CAS  PubMed  Google Scholar 

  160. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581–586.

    Article  CAS  PubMed  Google Scholar 

  161. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003;170:1481–1489.

    Article  CAS  PubMed  Google Scholar 

  162. Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol. 2004;40:904–909.

    Article  CAS  PubMed  Google Scholar 

  163. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664.

    Article  CAS  PubMed  Google Scholar 

  164. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413–419.

    Article  PubMed  Google Scholar 

  165. Furumoto Y, Asano T, Sugita T, et al. Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis. BMC Gastroenterol. 2015;15:144.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  166. Umemura T, Katsuyama Y, Yoshizawa K, et al. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS ONE. 2014;9:e100565.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  167. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712–2726.

    Article  PubMed  Google Scholar 

  168. Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting hepatic fibrosis in autoimmune hepatitis. Dig Dis Sci. 2016;61:3118–3139.

    Article  CAS  PubMed  Google Scholar 

  169. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 2012;55:522–529.

    Article  PubMed  Google Scholar 

  170. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–1629.

    Article  CAS  PubMed  Google Scholar 

  171. Czaja AJ. Hepatocellular cancer and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459–1476.

    Article  CAS  PubMed  Google Scholar 

  172. Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013;38:343–364.

    Article  CAS  PubMed  Google Scholar 

  173. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848–857.

    Article  CAS  PubMed  Google Scholar 

  174. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828–1835.

    Article  PubMed  Google Scholar 

  175. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol. 2012;46:155–161.

    Article  PubMed  Google Scholar 

  176. Yu JC, Neugut AI, Wang S, et al. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010;116:1801–1809.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980–1989.

    Article  PubMed  Google Scholar 

  178. Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723–732.

    Article  CAS  PubMed  Google Scholar 

  179. Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol. 2011;9:834–841.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Amarapurkar D, Dharod M, Amarapurkar A. Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol. 2015;36:36–45.

    Article  CAS  PubMed  Google Scholar 

  181. Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol. 2001;16:1144–1148.

    Article  CAS  PubMed  Google Scholar 

  182. Kim D, Eshtiaghpour D, Alpern J, et al. Access to primary care is associated with better autoimmune hepatitis outcomes in an urban county hospital. BMC Gastroenterol. 2015;15:91.

    Article  PubMed  PubMed Central  Google Scholar 

  183. Corpechot C, Gaouar F, Chretien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56:218–224.

    Article  CAS  PubMed  Google Scholar 

  184. Lammert C, Nguyen DL, Juran BD, et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis. 2013;45:589–594.

    Article  PubMed  PubMed Central  Google Scholar 

  185. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014;34:265–272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Chong CW, Ahmad AF, Lim YA, et al. Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia. Sci Rep. 2015;5:13338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Zhang J, Guo Z, Xue Z, et al. A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. ISME J. 2015;9:1979–1990.

    Article  PubMed  PubMed Central  Google Scholar 

  188. Segata N. Gut microbiome: westernization and the disappearance of intestinal diversity. Curr Biol. 2015;25:R611–R613.

    Article  CAS  PubMed  Google Scholar 

  189. Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS ONE. 2013;8:e53838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691–14696.

    Article  PubMed  PubMed Central  Google Scholar 

  191. Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J. 1980;281:772–775.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Chan ER, Hester J, Kalady M, et al. A novel method for determining microflora composition using dynamic phylogenetic analysis of 16S ribosomal RNA deep sequencing data. Genomics. 2011;98:253–259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Ma Y, Shi N, Li M, Chen F, Niu H. Applications of next-generation sequencing in systemic autoimmune diseases. Genomics Proteomics Bioinform. 2015;13:242–249.

    Article  Google Scholar 

Download references

Author’s contribution

Albert J. Czaja, MD, researched, designed, and wrote this article. The tables are original, constructed by Dr. Czaja, fully referenced, and developed solely for this review.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Professor Emeritus of Medicine, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN, 55905, USA

    Albert J. Czaja

Authors
  1. Albert J. Czaja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert J. Czaja.

Ethics declarations

Conflict of interest

The author declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Czaja, A.J. Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci 62, 2277–2292 (2017). https://doi.org/10.1007/s10620-017-4675-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4675-y

Keywords

Search

Navigation